Drugs / CB-010
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06752876 | Dec 2027 → Apr 2029 | lupus nephritis, systemic lupus erythematosus | Caribou Biosciences, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04637763 | May 2021 → Aug 2025 | B-cell non-Hodgkin lymphoma | Caribou Biosciences, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04637763 ↗ |
| Modality | CRISPR / gene editing | “CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.” NCT04637763 ↗ |
| Target | CD19 | “CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.” NCT04637763 ↗ |